Diabetes

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Unemployment rates compounded with high medical costs plague the diabetes community during the coronavirus disease 2019 (COVID-19) pandemic.

“I just hope that pharmacists’ judgment can soon be a contributing factor in pharmacotherapy decisions made by PBMs and insurance companies.”

In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.

Individuals with type 2 diabetes who exhibit extreme sleep duration hours may have a higher risk of death than individuals without diabetes.

Type 2 diabetes risk prediction is improved by observing changes in gut bacteria, a study finds.

Xeris Pharmaceuticals’ new glucagon injection (Gvoke HypoPen), a ready-to-use glucagon formulation in a premixed autoinjector, is now available by prescription.

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

The CDC has identified the pharmacy sector as a key partner in offering its lifestyle change-based program for patients with high risk for type 2 diabetes.

The first and only one of its kind, metoclopramide nasal spray offers relief to often debilitating symptoms of the gastrointestinal disease.

In response to the study, the NYC Department of Health is pursuing large-scale implementation of this approach, targeting diabetes hot spots across the city through public health messaging, mailed print materials, and Care Calls.

“We know that if we don’t address these potential difficulties before they occur, the burden to families can be devastating and the health care costs are tremendous.”

A study presented at the American Diabetes Association 80th Annual Scientific Sessions examined the impact of digital Diabetes Self-Management Support systems.

Abbott’s FreeStyle Libre 2 is an integrated continuous glucose monitoring system for adults and children ages 4 and older with diabetes.

A study presented during the American Diabetes Association 80th Scientific Sessions focused on assessing preference and attitudes from patients with diabetes, their caregivers, and acquaintances.

New findings from a study presented at the ADA’s 80th Scientific Sessions showed a dramatic drop in diabetic ketoacidosis hospitalizations in patients who used the FreeStyle Libre system

A poster presented at ADA’s 80th Scientific Sessions examines the effects of interactive pharmacist insulin teaching for patients with diabetes prior to hospital discharge.

Presented during ADA’s 80th Scientific Sessions, results from an analysis of a 6-month telehealth intervention showed sustained improvements in glycemic control in patients with diabetes.

An analysis focused on patients with type 2 diabetes in rural regions, where accessibility to physicians is often limited.

Pharmacists must be tuned in to the latest technology for patients who monitor blood glucose.

Carla Cox, PhD, registered dietician and certified diabetes educator, discusses key information about COVID-19 that individuals with diabetes should know.

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.

Apotex Corp is voluntarily recalling all lots of metformin hydrochloride extended-release tablets, USP 500 mg, within expiry to retail level.

CMS is reducing insulin copays for seniors who are eligible for Medicare via an executive order from President Donald Trump.

Months after FDA said it was investigating the carcinogenic ingredient NDMA in metformin products, the agency’s testing has found elevated levels of NDMA in extended release metformin, but not in the immediate release formulation.